Positive Outlook for ACADIA Pharmaceuticals: Strong Financial Performance and Promising Pipeline Developments Justify Buy Rating

Needham analyst Ami Fadia maintained a Buy rating on ACADIA Pharmaceuticals (ACAD – Research Report) today and set a price target of $27.00.

Ami Fadia’s rating is based on several positive indicators for ACADIA Pharmaceuticals. The company’s first-quarter earnings per share exceeded expectations, driven by higher-than-anticipated revenues from Nuplazid and reduced selling, general, and administrative expenses. This financial performance suggests a strong market position and effective cost management.
Additionally, ACADIA’s management has maintained its revenue guidance for 2025 while increasing its research and development budget, indicating a commitment to advancing its pipeline. The acceleration of the Phase 3 COMPASS study and the anticipated early readout of the ACP-101 Phase 3 trial are seen as positive developments that could enhance the company’s growth prospects. These factors collectively contribute to the Buy rating, as they suggest potential for future financial and operational success.

In another report released today, RBC Capital also maintained a Buy rating on the stock with a $26.00 price target.